Company intelligence / Profile preview

Merrimack Pharmaceuticals

Cambridge, Massachusetts, United Statesmerrimack.com ↗

Ownership: Public · MACK
Development stage: Commercial

Overview

Merrimack was a clinical-stage biopharma company developing targeted therapies for cancer. Its lead commercial product was Onivyde® for pancreatic cancer. After selling Onivyde to Ipsen in 2017 and discontinuing all remaining clinical programs due to efficacy or safety failures by mid–2019, the company ceased R&D activities and ultimately dissolved in May 2024[4][5][7].

Therapeutic areas: Oncology
Modalities: Antibodies (monoclonal and bispecific)fusion proteinssmall molecules
Industry: Biotech

Drug pipeline

15 assets

irinotecan liposome injection

Approved

14 more assets in the full pipeline.

Partnerships

Ipsen S.A. – acquired Onivyde® from Merrimack in April 2017 for ~$1 billion with contingent milestones[1][5]Elevation Oncology – acquired rights to MM–121 and MM–111 in July 2019 with milestone payments possible[5]

Beyond the preview

Go deeper on Merrimack Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merrimack Pharmaceuticals.